T1	p 128 187	patients with hemodynamically decompensated heart failure .
T2	p 540 651	16 decompensated heart failure patients in an invasive , randomized , double-blind , placebo-controlled study .
T3	i 68 124	steady-state infusion of human brain natriuretic peptide
T4	i 199 239	Human brain natriuretic peptide ( hBNP )
T5	i 388 392	hBNP
T6	i 516 520	hBNP
T7	i 625 643	placebo-controlled
T8	i 733 742	( placebo
T9	i 760 764	hBNP
T10	i 928 934	hBNP .
T11	i 955 959	hBNP
T12	i 1026 1030	hBNP
T13	i 1175 1179	hBNP
T14	i 1323 1327	hBNP
T15	i 1425 1439	placebo , hBNP
T16	i 1528 1534	hBNP ;
T17	i 1657 1661	hBNP
T18	i 1736 1740	hBNP
T19	i 1868 1872	hBNP
T20	i 1888 1892	hBNP
T21	o 6 62	Systemic hemodynamic , neurohormonal , and renal effects
T22	o 328 384	systemic hemodynamic , neurohormonal , and renal effects
T23	o 1009 1025	adverse events .
T24	o 1066 1126	right atrial pressure and pulmonary capillary wedge pressure
T25	o 1207 1235	systemic vascular resistance
T26	o 1356 1369	cardiac index
T27	o 1400 1412	heart rate .
T28	o 1450 1508	plasma norepinephrine and aldosterone . Renal hemodynamics
T29	o 1581 1601	natriuretic effect .
T30	o 1634 1653	hemodynamic effects
T31	o 1681 1731	cardiac preload and systemic vascular resistance .
T32	o 1755 1769	cardiac output
T33	o 1789 1801	heart rate .
T34	o 1806 1850	Plasma norepinephrine and aldosterone levels